SCHEMBL3072305

SCHEMBL3072305

C=Cc1cc(C(=O)O)cc(-c2ccc(C)cc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.46
KDM1A O60341 3/20 0.46
HDAC6 Q9UBN7 2/20 0.46
AKR1C3 P42330 5/20 0.44
JAK2 O60674 1/20 0.44
AKR1C4 P17516 1/20 0.40
PTGS2 P35354 1/20 0.40
AKR1C2 P52895 3/20 0.40
HDAC2 Q92769 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
CTSA P10619 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
RARB P10826 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075053 0.86 HDAC1 (0.46) HDAC1KDM1AHDAC6AKR1C3JAK2
SCHEMBL3068683 0.83 HDAC1 (0.46) HDAC1KDM1AHDAC6AKR1C3AKR1C4
SCHEMBL16195521 0.79 DHODH (0.52) AKR1C3JAK2AKR1C4PTGS2AKR1C2
SCHEMBL3641384 0.76 ALDH1A1 (0.53) HDAC1KDM1AHDAC6AKR1C3JAK2
SCHEMBL18397597 0.76 AKR1C3 (0.64) HDAC6AKR1C3JAK2AKR1C2MRGPRX4
SCHEMBL21093877 0.75 HDAC1 (0.42) HDAC1KDM1AHDAC6AKR1C3PTGS2
SCHEMBL2262047 0.73 KDM1A (0.59) HDAC1KDM1AHDAC6AKR1C3JAK2
SCHEMBL1070059 0.73 LDHA (0.41) HDAC6
SCHEMBL28329451 0.72 TPMT (0.61) SLC22A8CA12CA1CA9
SCHEMBL16195147 0.72 DHODH (0.51) AKR1C3JAK2PTGS2AKR1C2RARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215049-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2019-06-12 EP disclosed
US-8247401-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2012-08-21 US disclosed
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2010-10-21 US disclosed
EP-2215049-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 EP disclosed
WO-2009058298-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 HDAC1 3458/4885KDM1A 3692/4885HDAC6 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.